When to Switch? Biologically Experienced Psoriasis Patients


Activity Info

Upon completion of the activity, participants should be able to:
1. Explain why changes in response to brand-infliximab (Remicade) and the presence of anti-drug antibodies are important indicators of how a patient will respond to a switch to biosimilar infliximab
2. Make informed decisions about when and when not to switch from brand-infliximab (Remicade) to biosimilar infliximab

CME/CE credit is no longer available for this activity.